Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference
03 Noviembre 2023 - 6:30AM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical
company focused on the identification, acquisition, development and
commercialization of novel therapies for debilitating rare and
orphan diseases, today announced that it is scheduled to
participate in a fireside chat at the 2023 UBS Biopharma Conference
on Wednesday, November 8th 2023 at 2:00 pm ET, as well as 1x1
meetings.
Visit the Investors and Media section of Mirum’s corporate
website for webcast links and additional information.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to transforming the treatment of rare diseases affecting
children and adults. Mirum has three approved medications:
LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid)
capsules, and CHENODAL® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of
cholestatic pruritus in patients with Alagille syndrome in the U.S.
(three months and older), in Europe (two months and older), and in
Canada. Mirum has also submitted LIVMARLI for approval in the U.S.
in cholestatic pruritus in PFIC patients three months of age and
older and in Europe in PFIC for patients two months of age and
older. CHOLBAM is FDA-approved for the treatment of bile acid
synthesis disorders due to single enzyme deficiencies and
adjunctive treatment of peroxisomal disorders in patients who show
signs or symptoms or liver disease. CHENODAL has received medical
necessity recognition by the FDA to treat patients with
cerebrotendinous xanthomatosis (CTX).
Mirum’s late-stage pipeline includes three investigational
treatments for debilitating liver diseases. The LIVMARLI
development program includes the Phase 2b EMBARK study for biliary
atresia. Mirum’s second investigational IBAT inhibitor is
volixibat, which is being evaluated in two potentially
registrational studies including the Phase 2b VISTAS study for
primary sclerosing cholangitis and Phase 2b VANTAGE study for
primary biliary cholangitis. Lastly, CHENODAL, has been evaluated
in a Phase 3 clinical study, RESTORE, to treat patients with
CTX.
To learn more about Mirum, visit mirumpharma.com and follow
Mirum on Facebook, LinkedIn, Instagram and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231103747669/en/
Investor Contacts: Andrew McKibben investors@mirumpharma.com
Sam Martin Argot Partners ir@mirumpharma.com
Media Contact: Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Gráfica de Acción Histórica
De May 2023 a May 2024